Sabinsa Files Comments on FDAAA 912

PISCATAWAY, N.J.—New FDA regulations could potentially force new dietary ingredients off the market or stymie innovation in the nutraceutical arena, Sabinsa Corp. argued in comments filed with FDA regarding the agency’s implementation of Section 912 of the Food and Drug Administration Amendments Act of 2007 (FDAAA). Sabinsa’s comments were primarily directed at a provision of FDAAA that could potentially force new dietary ingredients (NDIs) off the market and erect a substantial barrier to entry to the food market for efficacious, safe ingredients.

“This has a potentially chilling effect on companies investing in science relating to dietary supplements,” said Jeff Lind, Sabinsa’s CEO. “Sabinsa believes that if the new law is applied to dietary supplements, manufacturers will be forced to make a ‘Hobson’s choice’ between conducting research on their products and marketing them as ‘food’.”